Psychopharmacology Clinical Trial Recruitment Challenges in Neurogenetic Syndromes: Lessons from an Open-Label Trial of Fluoxetine in Down Syndrome

Q: What type of study is this?

This is a Human Clinical Trial study.

Kimaya R. Gracias; Laura Sarnie; Michelle Palumbo; Caitlin Ravichandran; Christopher J. McDougle; Robyn P. Thom

doi:10.1177/10445463251379822

September 22, 2025Journal of Child and Adolescent Psychopharmacology

Psychopharmacology Clinical Trial Recruitment Challenges in Neurogenetic Syndromes: Lessons from an Open-Label Trial of Fluoxetine in Down Syndrome

View Full Paper

Ask AI

Bookmark

Share

Key Points

Psychopathology risk is notably high in neurogenetic syndromes, yet few trials have been done.
An open-label trial tested fluoxetine in participants with Down syndrome, facing significant recruitment hurdles.
Addressing recruitment challenges is critical to advancing psychopharmacological research in neurogenetic conditions.
Enhancing strategies for clinical trial participation is necessary to support vulnerable populations like those with Down syndrome.

Implication

Open-label trial with fluoxetine for individuals with Down syndrome reveals recruitment issues, highlighting a need for effective strategies.

Abstract

Background: Despite the increased risk for psychopathology in individuals with neurogenetic syndromes, very few psychopharmacology trials have been conducted in these populations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gracias et al. (2025) studied this question.

synapsesocial.com/papers/68d46fdc31b076d99fa6a48b https://doi.org/10.1177/10445463251379822

View Full Paper

Ask AI

Bookmark

Share

Psychopharmacology Clinical Trial Recruitment Challenges in Neurogenetic Syndromes: Lessons from an Open-Label Trial of Fluoxetine in Down Syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Psychopharmacology Clinical Trial Recruitment Challenges in Neurogenetic Syndromes: Lessons from an Open-Label Trial of Fluoxetine in Down Syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading